Conference LibraryGated
ESO-T01 · in vivo BCMA CAR-T (EsoBiotec) · phase 1
EsoBiotec 首款 in vivo CAR-T candidate · BCMA-targeted · 通过 ENaBL 第三代 immune-shielded lentiviral vector 在体内生成 CAR-T 细胞。 Phase 1 IIT trial 已启动(中国),9 patient cohort 数据已 published in Nature Medicine 2026 (PMID 41882404) + Lancet 2025 (DOI 10.1016/S0140-6736(25)01030-X)。
- Type
- product
- Domain
- conference
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- in_vivo_car_t_lentiviral
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "ESO-T01 phase 1 IIT clinical data · feasibility demonstration · NOT validated late-stage clinical model · not intended to guide individual patient treatment choices"
- modality
- lentiviral
- target_cell_type
- human T cell (in vivo · via T-cell-specific promoter ENaBL)
- cargo
- dna
- application
- in vivo BCMA CAR-T for r/r multiple myeloma
- development_stage
- phase_1
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.